Complications, GVHD, and outcome*
| Toxicity . | No. of patients . | ||
|---|---|---|---|
| Group A . | Group B . | All . | |
| Stomatitis | |||
| < 3rd degree | 5 | 15 | 20 |
| 3rd or 4th degree | 9 | 1 | 10 |
| Gastrointestinal tract | |||
| < 3rd degree | 9 | 11 | 20 |
| 3rd or 4th degree | 5 | 5 | 10 |
| Liver† | |||
| < 3rd degree | 8 | 8 | 16 |
| 3rd or 4th degree | 6 | 8 | 14 |
| Kidney‡ | |||
| < 3rd degree | 12 | 12 | 24 |
| 3rd or 4th degree | 2 | 4 | 6 |
| Lung | |||
| < 3rd degree | 12 | 11 | 23 |
| 3rd or 4th degree | 2 | 5 | 7 |
| Heart | |||
| < 3rd degree | 12 | 15 | 27 |
| 3rd or 4th degree | 2 | 1 | 3 |
| Acute GVHD | |||
| < grade 2 | 8 | 11 | 19 |
| Grade 2 | 4 | 5 | 9 |
| Grade 3 | 1 | 0 | 1 |
| Grade 4 | 1 | 0 | 1 |
| Chronic GVHD (in evaluable patients) | |||
| None | 7 | 11 | 18 |
| Limited | 2 | 2 | 4 |
| Extended | 2 | 3 | 5 |
| Rejection and relapse | |||
| Graft rejection | 1 | 1 | 2 |
| Relapse of disease | 6 | 1 | 7 |
| Treatment-related mortality | 2 | 2 | 4 |
| Dead | 5 | 2 | 7 |
| Alive | 9 | 14 | 23 |
| Toxicity . | No. of patients . | ||
|---|---|---|---|
| Group A . | Group B . | All . | |
| Stomatitis | |||
| < 3rd degree | 5 | 15 | 20 |
| 3rd or 4th degree | 9 | 1 | 10 |
| Gastrointestinal tract | |||
| < 3rd degree | 9 | 11 | 20 |
| 3rd or 4th degree | 5 | 5 | 10 |
| Liver† | |||
| < 3rd degree | 8 | 8 | 16 |
| 3rd or 4th degree | 6 | 8 | 14 |
| Kidney‡ | |||
| < 3rd degree | 12 | 12 | 24 |
| 3rd or 4th degree | 2 | 4 | 6 |
| Lung | |||
| < 3rd degree | 12 | 11 | 23 |
| 3rd or 4th degree | 2 | 5 | 7 |
| Heart | |||
| < 3rd degree | 12 | 15 | 27 |
| 3rd or 4th degree | 2 | 1 | 3 |
| Acute GVHD | |||
| < grade 2 | 8 | 11 | 19 |
| Grade 2 | 4 | 5 | 9 |
| Grade 3 | 1 | 0 | 1 |
| Grade 4 | 1 | 0 | 1 |
| Chronic GVHD (in evaluable patients) | |||
| None | 7 | 11 | 18 |
| Limited | 2 | 2 | 4 |
| Extended | 2 | 3 | 5 |
| Rejection and relapse | |||
| Graft rejection | 1 | 1 | 2 |
| Relapse of disease | 6 | 1 | 7 |
| Treatment-related mortality | 2 | 2 | 4 |
| Dead | 5 | 2 | 7 |
| Alive | 9 | 14 | 23 |